{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019558","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.038639+00:00","generated_at":"2026-06-01T23:04:18.249228+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pulmatrix Phase 1 data for inhaled DHE (PUR3100) published: rapid absorption, better tolerability vs IV DHE","bullets":["All PUR3100 doses showed mean Cmax above 1000 pg/mL efficacy threshold; Tmax 5 min vs 5.5 min for IV DHE.","Lower incidence of nausea (21% vs 86%), vomiting (0% vs 29%), and headache (16% vs 57%) compared to IV DHE.","Data published in Headache: The Journal of Head and Face Pain; FDA allowed Phase 2 study to proceed.","Company seeking financing or partnership to advance PUR3100 into Phase 2 for acute migraine."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019558","json":"https://secwatch.observer/filing/0001493152-24-019558.json","markdown":"https://secwatch.observer/filing/0001493152-24-019558.md","text":"https://secwatch.observer/filing/0001493152-24-019558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315224019558/0001493152-24-019558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315224019558/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:04:18.249228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}